Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: Results of the D-first study of Kanto CML study group.
Iriyama N, Fujisawa S, Yoshida C, Wakita H, Chiba S, Okamoto S, Kawakami K, Takezako N, Kumagai T, Inokuchi K, Ohyashiki K, Taguchi J, Yano S, Igarashi T, Kouzai Y, Morita S, Sakamoto J, Sakamaki H. Iriyama N, et al. Among authors: kouzai y. Am J Hematol. 2015 Apr;90(4):282-7. doi: 10.1002/ajh.23923. Epub 2015 Mar 2. Am J Hematol. 2015. PMID: 25530131 Free article. Clinical Trial.
Dasatinib cessation after deep molecular response exceeding 2 years and natural killer cell transition during dasatinib consolidation.
Kumagai T, Nakaseko C, Nishiwaki K, Yoshida C, Ohashi K, Takezako N, Takano H, Kouzai Y, Murase T, Matsue K, Morita S, Sakamoto J, Wakita H, Sakamaki H, Inokuchi K; Kanto CML and Shimousa Hematology Study Groups. Kumagai T, et al. Among authors: kouzai y. Cancer Sci. 2018 Jan;109(1):182-192. doi: 10.1111/cas.13430. Epub 2017 Nov 29. Cancer Sci. 2018. PMID: 29058817 Free PMC article. Clinical Trial.
Regulatory T cell inhibition by dasatinib is associated with natural killer cell differentiation and a favorable molecular response-The final results of the D-first study.
Najima Y, Yoshida C, Iriyama N, Fujisawa S, Wakita H, Chiba S, Okamoto S, Kawakami K, Takezako N, Kumagai T, Ohyashiki K, Taguchi J, Yano S, Igarashi T, Kouzai Y, Morita S, Sakamoto J, Sakamaki H, Inokuchi K. Najima Y, et al. Among authors: kouzai y. Leuk Res. 2018 Mar;66:66-72. doi: 10.1016/j.leukres.2018.01.010. Epub 2018 Feb 3. Leuk Res. 2018. PMID: 29407585 Clinical Trial.
Silent NK/T cell reactions to dasatinib during sustained deep molecular response before cessation are associated with longer treatment-free remission.
Kumagai T, Nakaseko C, Nishiwaki K, Yoshida C, Ohashi K, Takezako N, Takano H, Kouzai Y, Murase T, Matsue K, Morita S, Sakamoto J, Wakita H, Sakamaki H, Inokuchi K; Kanto CML, Shimousa Hematology Study Groups. Kumagai T, et al. Among authors: kouzai y. Cancer Sci. 2020 Aug;111(8):2923-2934. doi: 10.1111/cas.14518. Epub 2020 Jun 26. Cancer Sci. 2020. PMID: 32614159 Free PMC article. Clinical Trial.
Early cytotoxic lymphocyte expansion contributes to a deep molecular response to dasatinib in patients with newly diagnosed chronic myeloid leukemia in the chronic phase: results of the D-first study.
Iriyama N, Fujisawa S, Yoshida C, Wakita H, Chiba S, Okamoto S, Kawakami K, Takezako N, Kumagai T, Inokuchi K, Ohyashiki K, Taguchi J, Yano S, Igarashi T, Kouzai Y, Morita S, Sakamoto J, Sakamaki H. Iriyama N, et al. Among authors: kouzai y. Am J Hematol. 2015 Sep;90(9):819-24. doi: 10.1002/ajh.24096. Am J Hematol. 2015. PMID: 26103598 Free article. Clinical Trial.
Association of pleural effusion with an early molecular response in patients with newly diagnosed chronic-phase chronic myeloid leukemia receiving dasatinib: Results of a D-First study.
Hagihara M, Iriyama N, Yoshida C, Wakita H, Chiba S, Okamoto S, Kawakami K, Takezako N, Kumagai T, Inokuchi K, Ohyashiki K, Taguchi J, Yano S, Igarashi T, Kouzai Y, Morita S, Sakamoto J, Sakamaki H. Hagihara M, et al. Among authors: kouzai y. Oncol Rep. 2016 Nov;36(5):2976-2982. doi: 10.3892/or.2016.5110. Epub 2016 Sep 20. Oncol Rep. 2016. PMID: 27665844 Clinical Trial.
Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.
Shiseki M, Yoshida C, Takezako N, Ohwada A, Kumagai T, Nishiwaki K, Horikoshi A, Fukuda T, Takano H, Kouzai Y, Tanaka J, Morita S, Sakamoto J, Sakamaki H, Inokuchi K. Shiseki M, et al. Among authors: kouzai y. Int J Clin Oncol. 2017 Oct;22(5):972-979. doi: 10.1007/s10147-017-1141-y. Epub 2017 May 26. Int J Clin Oncol. 2017. PMID: 28550414 Free PMC article. Clinical Trial.
Clinical efficacy and safety of biapenem for febrile neutropenia in patients with underlying hematopoietic diseases: a multi-institutional study.
Nakagawa Y, Suzuki K, Hirose T, Chou T, Fujisawa S, Kida M, Usuki K, Ishida Y, Taniguchi S, Kouzai Y, Tomoyasu S, Miyazaki K, Higashihara M, Ando K, Aoki S, Arai A, Akiyama N, Hatake K, Okamoto S, Dan K, Ohyashiki K, Urabe A. Nakagawa Y, et al. Among authors: kouzai y. J Infect Chemother. 2011 Feb;17(1):58-67. doi: 10.1007/s10156-010-0075-3. Epub 2010 Jul 3. J Infect Chemother. 2011. PMID: 20602137 Clinical Trial.
A phase I/II trial of intrabone marrow cord blood transplantation and comparison of the hematological recovery with the Japanese nationwide database.
Kurita N, Gosho M, Yokoyama Y, Kato T, Obara N, Sakata-Yanagimoto M, Hasegawa Y, Uchida N, Takahashi S, Kouzai Y, Atsuta Y, Kurata M, Ichinohe T, Chiba S. Kurita N, et al. Among authors: kouzai y. Bone Marrow Transplant. 2017 Apr;52(4):574-579. doi: 10.1038/bmt.2016.319. Epub 2017 Jan 9. Bone Marrow Transplant. 2017. PMID: 28067880 Clinical Trial.
Effect of methotrexate dose in graft-versus-host disease prophylaxis after single-unit cord blood transplantation in adult acute myeloid leukemia.
Terakura S, Kuwatsuka Y, Sugita J, Takahashi S, Ozawa Y, Ozeki K, Yoshioka S, Nakamae H, Kawakita T, Sawa M, Morishige S, Najima Y, Katsuoka Y, Sakaida E, Kouzai Y, Kimura T, Ichinohe T, Fukuda T, Atsuta Y, Murata M, Teshima T. Terakura S, et al. Among authors: kouzai y. Int J Hematol. 2021 Jun;113(6):840-850. doi: 10.1007/s12185-021-03097-8. Epub 2021 Feb 21. Int J Hematol. 2021. PMID: 33611725 Clinical Trial.
50 results